• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.05% Nasdaq Down0.18%

    Alimera Sciences, Inc. (ALIM)

    -NasdaqGM
    1.92 Down 0.29(13.12%) May 5, 3:59PM EDT
    ProfileGet Profile for:
    Alimera Sciences, Inc.
    6120 Windward Parkway
    Suite 290
    Alpharetta, GA 30005
    United States - Map
    Phone: 678-990-5740
    Fax: 678-990-5744
    Website: http://www.alimerasciences.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Drug Manufacturers - Major
    Full Time Employees:70

    Business Summary 

    Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States, Germany, Portugal, and the United Kingdom. The company focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient’s eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a constant micro-dose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. It has license agreement with pSivida US, Inc. for the development and sale of ILUVIEN, and a delivery device to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans (other than uveitis) or to treat DME. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Alimera Sciences, Inc.

    Corporate Governance 
    Alimera Sciences, Inc.’s ISS Governance QuickScore as of May 1, 2016 is 9. The pillar scores are Audit: 5; Board: 4; Shareholder Rights: 8; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. Charles Daniel Myers , 62
    Co-Founder, Chief Exec. Officer and Director
    649.00K0.00
    Mr. Richard S. Eiswirth Jr., 48
    Pres, Chief Financial Officer and Sec.
    479.00K54.00K
    Mr. David R. Holland , 52
    Co-Founder and Sr. VP of Sales & Marketing
    419.00K21.00K
    Dr. Kenneth Green Ph.D., 58
    Chief Scientific Officer and Sr. VP
    426.00K45.00K
    Mr. Philip Ashman Ph.D., 51
    Sr. VP and European Managing Director
    409.00K0.00
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders